Kathryn Albert, PA
Medical · Wasilla, AKNPI 1356754618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 25.6% of the total. Among medical clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Amgen$468
- Lilly USA, LLC$388
- GSK$362
- Takeda Pharmaceuticals U.S.A., Inc.$250
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,35599%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,385 |
| AstraZeneca | 53 | $1,002 |
| Amgen | 20 | $468 |
| Lilly USA, LLC | 18 | $388 |
| GSK | 17 | $362 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $250 |
| Astellas Pharma US Inc | 7 | $203 |
| Sanofi-aventis U.S. LLC | 7 | $142 |
| Nestle Healthcare Nutrition Inc. | 6 | $137 |
| Novo Nordisk | 6 | $125 |
| Merck | 7 | $112 |
| Aimmune Therapeutics, Inc. | 5 | $111 |
| Teva Pharmaceuticals USA, Inc. | 5 | $103 |
| Novartis | 4 | $100 |
| Pfizer | 4 | $84 |
| Exact Sciences | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $68 |
| Biohaven Pharmaceuticals, Inc. | 3 | $58 |
| Antares Pharma, Inc. | 3 | $52 |
| Lundbeck LLC | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $34 |
| Eisai Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$5,417 in reported general payments places this provider in the 95th percentile of 140 medical providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 41 | $56,113 |
| FarxigaDapagliflozin Propanediol | 35 | $52,365 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $37,833 |
| EliquisApixaban | 18 | $30,148 |
| JanuviaSitagliptin Phosphate | 17 | $26,772 |
| OzempicSemaglutide | 15 | $25,437 |
| MyrbetriqMirabegron | 13 | $15,429 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $9,945 |
| Dexlansoprazole DrDexlansoprazole | 13 | $5,910 |
| SynthroidLevothyroxine Sodium | 52 | $4,360 |
| Fenofibric AcidFenofibric Acid (Choline) | 60 | $3,754 |
| Atorvastatin Calcium | 218 | $2,803 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $2,704 |
| Irbesartan | 61 | $2,569 |
| Lansoprazole | 22 | $2,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,002 | $52,36535 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $362 | $47,77835 claims |
| PfizerEliquis | $84 | $30,14818 claims |
| MerckJanuvia | $112 | $26,77217 claims |
| Novo NordiskOzempic | $125 | $25,43715 claims |
| Astellas Pharma US IncMyrbetriq | $203 | $15,42913 claims |
| AbbVieSynthroid | $1,385 | $4,36052 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 140 medical providers in Alaska.
Other medical in Wasilla
- Richard BlakeWasilla$19K
- Matthew LoudonWasilla$6K
- Karen ClementWasilla$5K
- Ksenia SokolovaWasilla$4K
- Katelyn StearnsWasilla$3K
- John MooreWasilla$2K
- Savanna SimmermanWasilla$1K
- Jessica van WulvenWasilla$1K
- Danielle McKinneyWasilla$1K
- Nathan FitzgeraldWasilla$761
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.